These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 23083634)

  • 1. Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.
    Dobi E; Monnien F; Kim S; Ivanaj A; N'Guyen T; Demarchi M; Adotevi O; Thierry-Vuillemin A; Jary M; Kantelip B; Pivot X; Godet Y; Degano SV; Borg C
    Clin Colorectal Cancer; 2013 Mar; 12(1):28-36. PubMed ID: 23083634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
    Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.
    Manceau G; Imbeaud S; Thiébaut R; Liébaert F; Fontaine K; Rousseau F; Génin B; Le Corre D; Didelot A; Vincent M; Bachet JB; Chibaudel B; Bouché O; Landi B; Bibeau F; Leroy K; Penault-Llorca F; Van Laethem JL; Demetter P; Tejpar S; Rossi S; Mosakhani N; Osterlund P; Ristamäki R; Sarhadi V; Knuutila S; Boige V; André T; Laurent-Puig P
    Clin Cancer Res; 2014 Jun; 20(12):3338-47. PubMed ID: 24771647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
    Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY
    Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
    Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
    J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
    Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
    Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
    Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
    Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
    Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC
    J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
    Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
    Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
    Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
    Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.
    Chang SC; Denne J; Zhao L; Horak C; Green G; Khambata-Ford S; Bray C; Celik I; Van Cutsem E; Harbison C
    Clin Colorectal Cancer; 2013 Sep; 12(3):195-203.e2. PubMed ID: 23978462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F
    J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
    J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
    Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
    Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.
    Lin JK; Lin AJ; Lin CC; Lan YT; Yang SH; Li AF; Chang SC
    J Surg Oncol; 2011 Nov; 104(6):661-6. PubMed ID: 21671463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.